Acumen Pharmaceuticals
(NASDAQ:ABOS)
$3.61
0.05[1.40%]
Last update: 1:59PM Get Real Time Here

GET A REPORT ON ABOS SENT RIGHT TO YOUR INBOX

Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.
Consensus Rating1
Buy
Highest Price Target1
$27.00
Lowest Price Target1
$8.00
Consensus Price Target1
$17.38

Analyst Rating Summary1

Analyst Ratings
Dec 23
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Deutsche Bank
Credit Suisse
HC Wainwright & Co.
B of A Securities
Cantor Fitzgerald

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Acumen Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
12/12/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69116.8%Deutsche Bank
Neena Bitritto-Garg
→ $8Initiates → BuyGet Alert
08/09/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69252.3%Credit Suisse
Judah Frommer
→ $13ReiteratesOutperform → OutperformGet Alert
08/09/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69306.5%HC Wainwright & Co.
Andrew Fein
→ $15ReiteratesBuy → BuyGet Alert
07/20/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69279.4%B of A Securities
Geoff Meacham
→ $14Reinstates → BuyGet Alert
07/17/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69252.3%Cantor Fitzgerald
Pete Stavropoulos
→ $13ReiteratesOverweight → OverweightGet Alert
07/17/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69306.5%HC Wainwright & Co.
Andrew Fein
→ $15ReiteratesBuy → BuyGet Alert
05/18/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69252.3%Cantor Fitzgerald
Pete Stavropoulos
→ $13Initiates → OverweightGet Alert
03/28/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69252.3%Credit Suisse
Judah Frommer
$16 → $13MaintainsOutperformGet Alert
03/28/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69306.5%HC Wainwright & Co.
Andrew Fein
→ $15Reiterates → BuyGet Alert
02/02/2023ABOSBuy Now
Acumen Pharmaceuticals
$3.69306.5%HC Wainwright & Co.
Andrew Fein
→ $15Reiterates → BuyGet Alert
11/15/2022ABOSBuy Now
Acumen Pharmaceuticals
$3.69333.6%Credit Suisse
Judah Frommer
$17 → $16MaintainsOutperformGet Alert
10/05/2022ABOSBuy Now
Acumen Pharmaceuticals
$3.69496.21%BTIG
Thomas Shrader
$15 → $22MaintainsBuyGet Alert
07/15/2022ABOSBuy Now
Acumen Pharmaceuticals
$3.69306.5%BTIG
Thomas Shrader
→ $15Initiates → BuyGet Alert
06/30/2022ABOSBuy Now
Acumen Pharmaceuticals
$3.69306.5%HC Wainwright & Co.
Andrew Fein
→ $15Initiates → BuyGet Alert
03/29/2022ABOSBuy Now
Acumen Pharmaceuticals
$3.69360.7%Credit Suisse
Judah Frommer
$26 → $17MaintainsOutperformGet Alert
01/21/2022ABOSBuy Now
Acumen Pharmaceuticals
$3.69279.4%B of A Securities
Geoff Meacham
$16 → $14UpgradeNeutral → BuyGet Alert
07/26/2021ABOSBuy Now
Acumen Pharmaceuticals
$3.69631.71%UBS
Colin Bristow
Initiates → BuyGet Alert
07/26/2021ABOSBuy Now
Acumen Pharmaceuticals
$3.69442.01%B of A Securities
Geoff Meacham
Initiates → NeutralGet Alert
07/26/2021ABOSBuy Now
Acumen Pharmaceuticals
$3.69604.61%Credit Suisse
Judah Frommer
Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Acumen Pharmaceuticals (ABOS)?

A

The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Deutsche Bank on December 12, 2023. The analyst firm set a price target for $8.00 expecting ABOS to rise to within 12 months (a possible 121.61% upside). 9 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?

A

The latest analyst rating for Acumen Pharmaceuticals (NASDAQ: ABOS) was provided by Deutsche Bank, and Acumen Pharmaceuticals initiated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on December 12, 2023 so you should expect the next rating to be made available sometime around December 12, 2024.

Q

Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?

A

While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a initiated with a price target of $0.00 to $8.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $3.61, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch